Latest Zoledronic acid Stories
NEW YORK, July 28, 2011 /PRNewswire/ -- A study published by ITG this week revealed that U.S.
The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is eagerly awaiting the report of an FDA panel being convened in September to discuss Fosamax, and specifically whether the drug increases incidence of throat cancer. New York, NY (PRWEB) July 25, 2011 According to an article published by Bloomberg on July 21, in advance of an advisory panel meeting on September 9 to discuss the long-term safety of drugs used to treat...
THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVAÂ® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.
THOUSAND OAKS, Calif., June 27, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S.
The Rottenstein Law Group, which represents clients with claims stemming from the rare severe side effects of the drug Fosamax, urges those who have taken Fosamax to consult doctors to determine whether they are at risk for femur fractures, even in light of recent suggestions that the risks to patients are less than previously thought. New York, NY (PRWEB) June 06, 2011 According to a post on the Web site of the American Council on Science and Health on June 1: â€œA new study should...
A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds.
EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).